The UK’s National Institute for Health and Care Excellence (NICE) has opened a public consultation on the first updates to its health technology evaluations manual, which was published in January 2022.
The ‘Pro-innovation Regulation of Technologies Review – Life Sciences’, published at the end of May 2023, highlights areas where improvements can be made to the UK’s regulatory environment to further enable innovation and a thriving life sciences sector. It presents ambitious ideas on developing innovation pathways and ways to support and retain talent in the regulatory organisations to ensure speed to market for new products.
With Mental Health Awareness Week 2023 having taken place from 15-21 May and focusing on anxiety, what advances have there been in this field to support those with mental health conditions? We examine the status of mental health therapy demand in the UK and whether the provision of digitally enabled treatments could be one way to help ease waiting times.
The UK’s National Institute for health and Care Excellence (NICE) has announced that it will be working closely with the Canadian Agency for Drugs and Technologies in Health (CADTH) and the US Institute for Clinical and Economic Review (ICER) to find common ground and smooth processes around the handling of confidential information about health technologies.
New research has found that the public believes a new approach should be adopted for making funding decisions about treatments for rare diseases. The report ‘Rare insights: examining the social values of treating rare diseases’, was commissioned by the UK BioIndustry Association’s (BIA) Rare Disease Industry Group (RDIG).
Wellcome has awarded £1.8m to the Medicines and Healthcare products Regulatory Agency (MHRA) and the National Institute for Health and Care Excellence (NICE) so that they can investigate and produce guidance on regulation of digital mental health tools.
The National Institute for Health and Care Excellence (NICE) plans to speed up its processes for evaluating lower-risk treatments using a lighter touch approach. This will free up time to consider the increasing number of more complex applications. NICE states that this method will make its assessments faster, enabling quicker access to promising new treatments.
